Clinical trials were undertaken in patients with functional digestive disorders, non-ulcer dyspepsia, and irritable bowel syndrome.
The results reported in January's Expert Opinion on Investigational Drugs, showed that the drug relieved abdominal pain after 6 weeks of treatment.
Fedotozine is derived from the arylacetamide series and is selective for the kappa-1a-opioid receptor subtype.
|Fedotozine is selective for the kappa-1a-opioid receptor, where it acts as an agonist.|
|Expert Opinion on Investigational Drugs|
Pharmacological studies have shown that fedotozine exerts a peripheral anti-nociceptive action, comparable with that of other kappa-agonists.
Its main effects have been demonstrated at the level of the afferent nerve pathways originating from the gut. Fedotozine alters the processing of visceral sensations along these pathways, and, hence, the perceptions of gut stimuli at the brain level, explains researcher M. Delvaux.
Fedotozine modifies reflexes induced in various pathological conditions, such as experimental inflammation of the gut, chemically-induced peritonitis or post-operative ileus. The drug also decreases the nociceptive reflexes triggered by noxious gut distension in animals.
In humans, fedotozine has been found to decrease the perception of gut distension, both in physiological and pathological conditions.
Delvaux concluded from the research that, "Kappa-opioid receptors remain an interesting area for future development of new treatments for abdominal pain in patients with functional digestive disorders."